DOP2021000254A - Compuestos de pirrolidina - Google Patents
Compuestos de pirrolidinaInfo
- Publication number
- DOP2021000254A DOP2021000254A DO2021000254A DO2021000254A DOP2021000254A DO P2021000254 A DOP2021000254 A DO P2021000254A DO 2021000254 A DO2021000254 A DO 2021000254A DO 2021000254 A DO2021000254 A DO 2021000254A DO P2021000254 A DOP2021000254 A DO P2021000254A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- formula
- compounds
- pyrrolidine compounds
- nhso2nh
- ch2nhch2
- Prior art date
Links
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical class C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona compuestos de la Fórmula en donde L se selecciona del grupo que consiste en -CH2NHCH2-, -CH2NH-, -NH-, -S-, -S(O)-, -S(O)2-, -O-, -OCH2-, -OCH2CH2O-, -NHSO2NH-, y o una sal farmacéuticamente aceptable de estos; un compuesto de la fórmula: , procesos para preparar los compuestos y sus sales, una composición farmacéutica y métodos para tratar pacientes que necesiten dicho tratamiento.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19382477 | 2019-06-07 | ||
| PCT/US2020/035825 WO2020247429A1 (en) | 2019-06-07 | 2020-06-03 | Pyrrolidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2021000254A true DOP2021000254A (es) | 2022-01-16 |
Family
ID=66821161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2021000254A DOP2021000254A (es) | 2019-06-07 | 2021-12-07 | Compuestos de pirrolidina |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11286249B2 (es) |
| EP (1) | EP3980409A1 (es) |
| JP (2) | JP6940717B2 (es) |
| KR (3) | KR102477481B1 (es) |
| CN (1) | CN114008021A (es) |
| AU (1) | AU2020287599B2 (es) |
| BR (1) | BR112021023347A2 (es) |
| CA (1) | CA3140869A1 (es) |
| CL (1) | CL2021003202A1 (es) |
| CO (1) | CO2021016295A2 (es) |
| CR (1) | CR20210602A (es) |
| DO (1) | DOP2021000254A (es) |
| EA (1) | EA202193007A1 (es) |
| EC (1) | ECSP21088515A (es) |
| IL (1) | IL288174A (es) |
| JO (1) | JOP20210319A1 (es) |
| MA (1) | MA56115A (es) |
| MX (1) | MX2021014913A (es) |
| PE (1) | PE20220134A1 (es) |
| SG (1) | SG11202113244UA (es) |
| WO (1) | WO2020247429A1 (es) |
| ZA (1) | ZA202109251B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3235992A1 (en) | 2021-11-03 | 2023-05-11 | Liang Tan | Substituted phenylpropionic acid derivative and use thereof |
| WO2023146785A1 (en) | 2022-01-26 | 2023-08-03 | Eli Lilly And Company | Pyrrolidine compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2003016265A1 (ja) * | 2001-08-17 | 2004-12-02 | エーザイ株式会社 | 環状化合物およびｐｐａｒアゴニスト |
| AU2003300438A1 (en) * | 2003-12-24 | 2005-08-03 | Esperion Therapeutics, Inc. | Ether compounds and compositions for cholesterol management and related uses |
| CA2549995C (en) * | 2003-12-24 | 2011-11-15 | Esperion Therapeutics, Inc. | Ketone compounds and compositions for cholesterol management and related uses |
-
2020
- 2020-06-03 SG SG11202113244UA patent/SG11202113244UA/en unknown
- 2020-06-03 WO PCT/US2020/035825 patent/WO2020247429A1/en active Application Filing
- 2020-06-03 JP JP2021505713A patent/JP6940717B2/ja active Active
- 2020-06-03 MA MA056115A patent/MA56115A/fr unknown
- 2020-06-03 KR KR1020217040065A patent/KR102477481B1/ko active IP Right Grant
- 2020-06-03 CN CN202080041924.XA patent/CN114008021A/zh active Pending
- 2020-06-03 KR KR1020227043106A patent/KR102629923B1/ko active IP Right Grant
- 2020-06-03 JO JOP/2021/0319A patent/JOP20210319A1/ar unknown
- 2020-06-03 EA EA202193007A patent/EA202193007A1/ru unknown
- 2020-06-03 CR CR20210602A patent/CR20210602A/es unknown
- 2020-06-03 US US17/056,144 patent/US11286249B2/en active Active
- 2020-06-03 MX MX2021014913A patent/MX2021014913A/es unknown
- 2020-06-03 BR BR112021023347A patent/BR112021023347A2/pt unknown
- 2020-06-03 CA CA3140869A patent/CA3140869A1/en active Pending
- 2020-06-03 KR KR1020247002433A patent/KR20240014618A/ko active Application Filing
- 2020-06-03 EP EP20747210.1A patent/EP3980409A1/en active Pending
- 2020-06-03 AU AU2020287599A patent/AU2020287599B2/en active Active
- 2020-06-03 PE PE2021002037A patent/PE20220134A1/es unknown
-
2021
- 2021-09-02 JP JP2021143227A patent/JP2021191784A/ja active Pending
- 2021-11-16 IL IL288174A patent/IL288174A/en unknown
- 2021-11-18 ZA ZA2021/09251A patent/ZA202109251B/en unknown
- 2021-11-30 CO CONC2021/0016295A patent/CO2021016295A2/es unknown
- 2021-12-01 CL CL2021003202A patent/CL2021003202A1/es unknown
- 2021-12-07 DO DO2021000254A patent/DOP2021000254A/es unknown
- 2021-12-07 EC ECSENADI202188515A patent/ECSP21088515A/es unknown
-
2022
- 2022-02-15 US US17/671,806 patent/US20220169636A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021023347A2 (pt) | 2022-04-12 |
| AU2020287599B2 (en) | 2023-10-19 |
| EA202193007A1 (ru) | 2022-03-25 |
| CO2021016295A2 (es) | 2021-12-10 |
| KR102629923B1 (ko) | 2024-01-30 |
| WO2020247429A1 (en) | 2020-12-10 |
| CL2021003202A1 (es) | 2022-09-09 |
| CR20210602A (es) | 2022-01-06 |
| IL288174A (en) | 2022-01-01 |
| MA56115A (fr) | 2022-04-13 |
| US20210253559A1 (en) | 2021-08-19 |
| JP6940717B2 (ja) | 2021-09-29 |
| EP3980409A1 (en) | 2022-04-13 |
| JP2021191784A (ja) | 2021-12-16 |
| MX2021014913A (es) | 2022-01-18 |
| AU2020287599A1 (en) | 2022-01-06 |
| US11286249B2 (en) | 2022-03-29 |
| JOP20210319A1 (ar) | 2023-01-30 |
| KR20220018494A (ko) | 2022-02-15 |
| PE20220134A1 (es) | 2022-01-27 |
| US20220169636A1 (en) | 2022-06-02 |
| CN114008021A (zh) | 2022-02-01 |
| SG11202113244UA (en) | 2021-12-30 |
| ECSP21088515A (es) | 2022-01-31 |
| JP2021524498A (ja) | 2021-09-13 |
| CA3140869A1 (en) | 2020-12-10 |
| KR20230004890A (ko) | 2023-01-06 |
| KR20240014618A (ko) | 2024-02-01 |
| KR102477481B1 (ko) | 2022-12-15 |
| ZA202109251B (en) | 2024-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20190124A (es) | Inhibidores de ssao de aminopirimidina | |
| CL2019002204A1 (es) | Compuestos inhibidores del vih. | |
| AR116604A1 (es) | Inhibidores de kras g12c | |
| CL2018001145A1 (es) | Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria | |
| DOP2021000254A (es) | Compuestos de pirrolidina | |
| CL2020000610A1 (es) | Compuestos de bisamida que activan el sarcómero y sus usos. | |
| CO2021005532A2 (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| BR112022011123A2 (pt) | Composto, processo para a preparação de um composto, usos de um composto, métodos para o tratamento de câncer e invenção | |
| CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| NI202000058A (es) | Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano | |
| UY37941A (es) | Derivados de bencimidazol y sus usos | |
| DOP2021000198A (es) | Compuestos y su uso en el tratamiento del cáncer | |
| EA202192433A1 (ru) | Соединения, полезные в терапии вич | |
| CO2024001367A2 (es) | Compuestos antivirales | |
| UY36123A (es) | Derivados de carboxamida | |
| CO2020004201A2 (es) | Inhibidor del receptor del factor de crecimiento epidérmico | |
| UY36124A (es) | Derivados de carboxamida | |
| AR124449A1 (es) | Inhibidores de sos1 y usos de los mismos | |
| AR127247A1 (es) | Inhibidores de cdk2 de ciclopentilpirazol | |
| CL2022001357A1 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
| DOP2019000299A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| BR112019008698A2 (pt) | método para tratar câncer num sujeito que precisa do mesmo e composição farmacêutica | |
| CO2021017202A2 (es) | Compuestos tricíclicos | |
| AR126251A1 (es) | Inhibidores de cdk2 |